<div class="container"><br />The British Consulate-General in Hong Kong plays a vital role in maintaining and developing relations between the United Kingdom, Hong Kong, and Macao. It also supports UK government interests and commercial ties in the region. The Department for Business and Trade (DBT) operates within the Consulate to deliver trade and investment services, helping UK companies successfully undertake business in Hong Kong and, in turn, supports Hong Kong firms investing in the UK. DBT leverages its’ specialist network to provide export guidance, market access support, and strategic advice.<br /><br />Website: <a style="color: #41aead;" href="https://www.business.gov.uk/" target="_blank" rel="noopener">www.business.gov.uk</a></div><div style="padding-bottom: 100px;"> </div>

British Consulate-General Hong Kong

<div class="container">Located in the heart of Hong Kong, City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education and for addressing global issues and empowering positive change.<br /><br />Website: <a style="color: #41aead;" href="http://www.cityu.edu.hk/hktech300/" target="_blank" rel="noopener">http://www.cityu.edu.hk/hktech300/</a></div><div style="padding-bottom: 100px;"> </div>

City University of Hong Kong

<div class="container"><br />Eieling Technology Limited, a research and transformation enterprise of the Hong Kong Polytechnic University, was incorporated in the Hong Kong Science Park in 2018, Eieling Technology focuses on the field of liver disease diagnosis and treatment, and insists on providing accurate and reliable intelligent liver health diagnosis solutions for global healthcare providers.<br /><br />Website: <a style="color: #41aead;" href="https://www.eieling.com/" target="_blank" rel="noopener">www.eieling.com</a></div><div style="padding-bottom: 100px;"> </div>

Eieling Technology

<div class="container"><br />Emerging Viral Diagnostics (Hong Kong) Limited (EVDL) is a Hong Kong-based MedTech company composed of a team of experienced interdisciplinary experts. By integrating academic, industrial, and research expertise, the company successfully transformed the "Fully Automated Multiplex Diagnostic System" from an unmet medical need into an innovative and practical diagnostic solution. In 2024, this system was recommended by the World Health Organization as an innovative health technology suitable for low-resource settings and was softly launched to the market. EVDL is committed to becoming a global leader in the diagnostic industry, continuously pushing Diagnosis beyond Boundaries!<br /><br />Website: <a style="color: #41aead;" href="https://www.emvdl.com/" target="_blank" rel="noopener">www.emvdl.com</a></div><div style="padding-bottom: 100px;"> </div>

Emerging Viral Diagnostics (HK) Limited

<div class="container">Finland is a global leader in innovation and technology. It excels in biotech and healthtech due to strong R&amp;D investment, unique genomic and biobank infrastructure, and comprehensive health data systems. Healthtech is Finland's largest hi-tech export segment. Companies are driving breakthroughs in oncology, neurology, ophthalmology, and orthopedics. <br /><br />Collaborative ecosystems in Finland unite academia, industry, and innovation startups and foster world-class research. At ASGH, Finland will host a country pavilion with 8-9 Finnish companies covering rehab, digital health, cancer diagnostics, wearables, and technologies for sleep and respiratory health. Welcome.<br /><br />Website: <a style="color: #41aead;" href="https://finlandabroad.fi/web/hkg/mission" target="_blank" rel="noopener">https://finlandabroad.fi/web/hkg/mission</a></div><div style="padding-bottom: 100px;"> </div>

Finland

<div class="container">Hong Kong Applied Science and Technology Research Institute is founded in 2000 by the Government of the Hong Kong Special Administrative Region. As Hong Kong’s largest government-funded research and development centre, ASTRI is a key force and super connector driving innovation and technology advancement in Hong Kong, the Greater Bay Area, and the global innovation ecosystem. Its technological strengths and capabilities enable AI powered, cross disciplinary ICT and advanced materials solutions across Smart City, FinTech, Digital Health and Life Sciences, New Industrialisation and Intelligent Manufacturing, Application-Specific Integrated Circuits (ASIC) and Advanced Electronics, New Energy and Energy Storage, and Green and ESG Technologies.<br /><br />Website: <a style="color: #41aead;" href="https://www.astri.org/" target="_blank" rel="noopener">https://www.astri.org/</a></div><div style="padding-bottom: 100px;"> </div>

 Hong Kong Applied Science and Technology Research Institute

<div class="container"><br />OPM Biosciences (Stock Code: 688293) is a leading provider of Cell Culture Media and CRDMO services. We have four fully cGMP-compliant plants, covering an overall area of 18,000m². Our exceptional performance has established us as the preferred supplier for over 320+ biologics (IND or BLA) worldwide. Our cGMP-compliant facilities support all stages of biologics development, from antibody discovery to IND and BLA manufacturing up to 2000L. Our dedicated team of experienced scientists is committed to excellence and has contributed to the development of over 200 biologics, supporting global clients in achieving successful IND applications with FDA and NMPA.<br /><br />Website: <a style="color: #41aead;" href="https://opmbiosciences.com/" target="_blank" rel="noopener">https://opmbiosciences.com/</a></div><div style="padding-bottom: 100px;"> </div>

OPM Biosciences

<div class="container">Jiangsu Jinfu Digital Tech Group Co., Ltd is positioned as the only integrated operator of digital RMB in China, a leading wholly state-owned digital financial enterprise, and a strategic engine for AI innovation-driven development in Suzhou. Adhering to the goal of "Leading Jiangsu and Serving the Nation", it drives business development through institutional and technological innovation, striving to create a new model of innovative and entrepreneurial state-owned enterprises.<br /><br />Website: <a style="color: #41aead;" href="https://www.jsjfsz.com/#/home" target="_blank" rel="noopener">https://www.jsjfsz.com/#/home</a></div><div style="padding-bottom: 100px;"> </div>

Suzhou

<div class="container"><br />Yangtze River Pharmaceutical Group Co., Ltd. (YRPG), founded in 1971, is one of China’s leading pharmaceutical enterprises, dedicated to delivering high-quality medicines and healthcare solutions to patients around the world.<br /><br />YRPG pursues balanced development across traditional Chinese medicine, chemical pharmaceuticals, and biologics. This strategy has formed a diversified portfolio covering multiple therapeutic areas, with more than 100 products exported to over 40 countries and regions.<br /><br />By expanding our global presence and integrating into the global health ecosystem, we are steadily progressing toward our vision of becoming a China-leading, world-class pharmaceutical and healthcare group.<br /><br />Website: <a style="color: #41aead;" href="https://en.yangzijiang.com/" target="_blank" rel="noopener">en.yangzijiang.com</a></div><div style="padding-bottom: 100px;"> </div>

Yangtze River Pharmaceutical Group Co., Ltd.

<div class="container">Thederma Shanghai is a biotech company focused on developing innovative therapies targeting the Aryl Hydrocarbon Receptor (AhR), a key immune regulator with profound immunomodulatory effects across inflammatory disorders.<br /><br />As the pioneer team behind the world’s first AhR-targeted therapeutic, the company has developed Zedman®, a non-steroidal topical AhR drug indicated for eczema in both adults and children, with outstanding efficacy and safety.<br /><br />Website: <a style="color: #41aead;" href="http://www.thederma.com/" target="_blank" rel="noopener">www.thederma.com</a></div><div style="padding-bottom: 100px;"> </div>

Zedman

Exhibitor

<div class="container"><strong>HK BIO-MED INNOTECH ASSOCIATION IS COMMITTED TO ESTABLISHING AN INNOVATIVE AND INTERNATIONAL BIOMEDICAL TECHNOLOGY HUB IN HONG KONG</strong><br /><br />Since establishment in 2017, we have aimed to actively introduce promising biomedical innovation projects and top-tier biomedical industries from overseas. By leveraging our biomedical ecosystem, we provide comprehensive support that includes, but is not limited to formulation of industrialization and commercial development strategies, fundraising and public listing assistance, corporate governance and auditing advisory, support in R&amp;D and IP protection, recommendations for policies and regulations, and assistance with clinical trial design and planning, etc.<br /><br />Our goal is to foster communication, exchange, and collaboration among the biomedical innovation technology industry, research institutions, the investment sector, and government in the areas of innovative R&amp;D, industrialization, regulatory coordination, investment, and financing.</div><div style="padding-bottom: 100px;"> </div>

 HK BIO-MED INNOTECH ASSOCIATION

<div class="container">The Hong Kong Productivity Council (HKPC) is a statutory body established in 1967, dedicated to enhancing local enterprises' productivity and competitive edge through applied research and technological services. It provides comprehensive overseas expansion support encompassing products, technology, manufacturing and management.<br /><br />HKPC's HealthTech and TCM in New Industrialisation Division, provides comprehensive “Cradle” support on full set of global expansion plans for each enterprise or project, including:<br /><br />- Market Research and Product Innovation &amp; Development<br />- Testing Services for Products or Drugs<br />- Regulation Compliance and Product Registration<br />- GMP Plant Design<br />- Smart Production Line or System Construction<br />- Overseas Certification<br />- Funding Applications and Policy Support</div><div style="padding-bottom: 100px;"> </div>

Hong Kong Productivity Council

<div class="container">The Association was incorporated in 2003 and was originally known as Hong Kong Medical and Healthcare Device Manufacturing Association as most of the members were manufacturers.<br><br>The Association was subsequently renamed as Hong Kong Medical and Healthcare Device Industries Association in October 2008 as our membership grew substantially and covered the entire value chain in the medical device industries.<br><br>Starting from March 2025, the Association renamed as Hong Kong MedTech Association (HKMTA).<br><br>The renaming symbolizes our continuous drive to foster innovation, strengthen industry collaborations and advance healthcare solutions. Together, we shape the next era of MedTech innovation.</div><div style="padding-bottom: 100px;"> </div>

HK MedTech Association

<div class="container">Established in 1907, The Law Society of Hong Kong is a statutory self-regulatory professional body representing over 13,000 solicitors, over 1,600 registered foreign lawyers from over 30 jurisdictions, and more than 1,000 registered local and foreign law firms. Collectively, these firms employ approximately 15,000 non-qualified personnel.<br /><br />As a staunch defender of the rule of law, The Law Society of Hong Kong plays a vital role in upholding the integrity of the legal profession. It serves as a key voice on matters of public interest, particularly those concerning the development of the legal profession and the practice of law in Hong Kong.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

The Law Society of Hong Kong

<div class="container">Hong Kong Biotechnology Organization is a nonprofit (tax-exempt under Section 88) dedicated to promoting best practices and raising awareness in the biotech industry. It offers value-added benefits to members, including students, researchers, entrepreneurs, industry bodies, and public/private sector representatives. Founded by experienced scientists with diverse backgrounds in life sciences, R&D, engineering, and business, the organization aims to create a global platform for Hong Kong’s biotech industry. It promotes international collaboration and provides expert opinions and technical advice to government, healthcare institutions, and the public.</div><div style="padding-bottom: 100px;"> </div>

Hong Kong Biotechnology Organization

<div class="container">About Greater Bay Area International Clinical Trial Institute (GBAICTI)<br><br>The Greater Bay Area International Clinical Trial Institute is a unified platform for clinical innovation, bringing together Hong Kong’s public and private medical resources to support research across the region. Located in the Hong Kong Park of the Hetao Shenzhen–Hong Kong Science and Technology Innovation Co-operation Zone, GBAICTI provides a one-stop platform for clinical trials and strengthens the Greater Bay Area’s role as a world-class research hub. Through cross-border collaboration, streamlined processes, real-world data application, and talent development, we accelerate medical innovation. Working with the Greater Bay Area International Clinical Trials Center, we coordinate multi-centre trials meeting national and international standards.</div><div style="padding-bottom: 100px;"> </div>

GBAICTI

<div class="container">Founded in 1968, the Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents 38 Research and Development pharmaceutical company members, including the world’s top 20. The Association also embraces clinical trial centres, distributors of innovative medicines, and service companies as members to complete the product life cycle.  HKAPI members account for more than 70% of prescriptions in Hong Kong.<br><br>HKAPI’s mission is to drive expedited access to innovative healthcare solutions for people in Hong Kong and Macao with the highest ethical standards.<br><br>Acting as a collaborative platform, HKAPI works with government, academia, patient groups, and communities to advance healthcare policies, improve regulations, and recommend strategies to enhance the R&D ecosystem in Hong Kong and the affordability and accessibility of medicines.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

HKAPI

<div class="container">The Biotechnology and Healthcare industries in Hong Kong have emerged as pivotal components of our city's innovative and high-value industrial landscape in an era marked by rapid advancements. To further propel the growth of these sectors alongside Hong Kong's broader new industrialisation and I&T ambitions, the Federation of Hong Kong Industries (FHKI) established its new 33rd industry group (the Biotechnology and Healthcare Council) in 2024.<br /><br />The Council encompasses a diverse array of enterprises, including those in biotechnology, biomedical, traditional Chinese medicine, health supplements, and health devices. Its primary objectives are to reflect Hong Kong's evolving industrial landscape, foster sectoral growth, and enhance service delivery to the pertinent businesses.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

FHKI Group 33 (Biotechnology and Healthcare Council)

<div class="container">Hong Kong Export Credit Insurance Corporation (HKECIC) was established in 1966 under the Hong Kong Export Credit Insurance Corporation Ordinance (Chapter 1115).  Through the provision of export credit insurance services, HKECIC protects Hong Kong exporters against non-payment risks arising from commercial and political events. Its insurance coverage spans more than 200 countries and markets, supporting Hong Kong and Chinese Mainland enterprises to go global.  The Government of the HKSAR provides a guarantee of HK$80 billion for the HKECIC’s statutory maximum liability.</div><br /><br /><div style="padding-bottom: 100px;"> </div>

HKECIC

Affiliate Partner

About the Summit

Honorary Advisors (2026)

Steering Committee (2026)

ASGH BROCHURE

Join ASGH Community

Previous Summit

Contact Us

ABOUT ASGH

Registration

Programme

Speakers

Sponsors and Partners

Asia Summit on Global Health Mission to Shenzhen

ASGH Deal-making

ASGH Business Hub

Innohealth Showcase

Continuing Medical Education (CME) and Continuing Professional Development (CPD) Hours/Points

House Rules

Special Airfares and Hotel Offers

Green Tips

Arrangement for Inclement Weather

EVENT DETAILS

Press Releases

Video Gallery

Photo Gallery

MEDIA

Biotech, Medical & Healthcare Industry in Hong Kong

Market Profile of Hong Kong

Case Studies and News

International Healthcare Week

INTELLIGENCE

HOMEPAGE

ABOUT THE SUMMIT

PREVIOUS SUMMIT

GENERAL ENQUIRIES

Participant Registration

2023 SPONSORS, GLOBAL AFFILIATE PARTNERS AND SUPPORTING MEDIA

EXHIBITION

InnoHealth Showcase

Business of Healthcare Advisory Zone

PRESS RELEASES

VIDEO GALLERY 2021

JOIN ASGH COMMUNITY

Hygiene Measures & Health Tips for Participants

BIOTECH, MEDICAL & HEALTHCARE INDUSTRY IN HONG KONG

PROGRAMME HIGHLIGHTS

Travel to Hong Kong

Welcome Message

PHOTO GALLERY 2022

VIDEO GALLERY 2023

Asia Summit on Global Health 2022

SPECIAL AIRFARES FROM CATHAY PACIFIC

ASGH Webinar and Seminar Series

webinar testing

Programme 2022

Speaker 2022

Participants 2022

GREEN TIPS

Asia Summit on Global Health 2023

Programme 2023

Speaker 2023

Participants 2023

VIDEO GALLERY 2022

PHOTO GALLERY 2023

Honorary Advisors (2025)

VIDEO GALLERY

Asia Summit on Global Health 2024

Speaker

participant list

2024 Honorary Advisors

Steering Committee (2025)

SPECIAL AIRFARES AND HOTEL OFFERS

ASGH 2025 floor plan

CASE STUDIES AND NEWS

Hong Kong private hospital taps into telemedicine in the Greater Bay Area

Strong push by innovative Chinese pharma firms to make Hong Kong the top biotech fundraising hub